Mianserin

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Mechanism only
Half-life: 6–39 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: mianserin · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

5-HT2A/2C blockade likely blunts effects, as with mirtazapine.

Human data with psilocybin: None known: no published human data with psilocybin
Half-life: 6–39 h (UK SmPC) (UK SmPC, checked 2026-09-30)

Evidence types on this record

ThMechanism only (theoretical)

1 listed · counted on reports

Blocks 5-HT2A (may blunt effects): Blocks the 5-HT2A receptor, the main receptor psilocybin acts through. Can reduce or block the psilocybin effect. Sources [2]

Official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

None linked

No condition named in state rules is linked to this medication.

Non-US product information
Brunton LL, Knollmann BC (eds). Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed. McGraw Hill, 2023., p. 373 — listed with 5HT2 antagonists